According to @ai_darpa, China has successfully engineered staple rice crops as bioreactors to produce 100% pure human albumin, eliminating dependence on human plasma donations. This biotechnology enables an annual output of 130 tons of medical-grade albumin with zero infection risk (source: @ai_darpa, Jan 2, 2026). AI-driven optimization of agricultural processes is central to this innovation, signaling a major shift from hospital-based blood sourcing to scalable, laboratory-managed crop production. The development offers significant business opportunities in biopharmaceutical manufacturing and the global healthcare supply chain, promising safer, more efficient, and scalable protein therapeutics.